Enhanced expression of Bruton's tyrosine kinase in B cells drives systemic autoimmunity by disrupting T cell homeostasis

Journal of Immunology

Volumn 197, Issue 1, 2016, Pages 58-67

  Corneth, Odilia B J ^a   De Bruijn, Marjolein J W ^a   Rip, Jasper ^a   Asmawidjaja, Patrick S ^a   Kil, Laurens P ^a,b   Hendriks, Rudi W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; CD19 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN M ANTIBODY; INDUCIBLE T CELL COSTIMULATOR; INTERLEUKIN 10; INTERLEUKIN 6; AGAMMAGLOBULINAEMIA TYROSINE KINASE; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL INTERACTION; CELL METABOLISM; CONTROLLED STUDY; CYTOKINE PRODUCTION; IN VIVO STUDY; MOUSE; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; AUTOIMMUNE DISEASES; C57BL MOUSE; CELL COMMUNICATION; GENETICS; HOMEOSTASIS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MUTATION; PHYSIOLOGY; PROMOTER REGION; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD19; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; CD40 LIGAND; CELL COMMUNICATION; HOMEOSTASIS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; PROMOTER REGIONS, GENETIC; PROTEIN-TYROSINE KINASES; T-LYMPHOCYTES;

EID: 84975231564     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600208     Document Type: Article

References (56)

1. Tsokos, G. C. 2011. Systemic lupus erythematosus. N. Engl. J. Med. 365: 2110-2121.
2. Wahren-Herlenius, M., and T. Dörner. 2013. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 382: 819-831.
3. Arbuckle, M. R., M. T. McClain, M. V. Rubertone, R. H. Scofield, G. J. Dennis, J. A. James, and J. B. Harley. 2003. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349: 1526-1533.
4. D'Cruz, D. P., M. A. Khamashta, and G. R. Hughes. 2007. Systemic lupus erythematosus. Lancet 369: 587-596.
5. Lessard, C. J., H. Li, I. Adrianto, J. A. Ice, A. Rasmussen, K. M. Grundahl, J. A. Kelly, M. G. Dozmorov, C. Miceli-Richard, S. Bowman, et al; UK Primary Sjögren's Syndrome Registry. 2013. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat. Genet. 45: 1284-1292.
6. Groom, J., S. L. Kalled, A. H. Cutler, C. Olson, S. A. Woodcock, P. Schneider, J. Tschopp, T. G. Cachero, M. Batten, J. Wheway, et al. 2002. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J. Clin. Invest. 109: 59-68.
7. Cui, Y., Y. Sheng, and X. Zhang. 2013. Genetic susceptibility to SLE: recent progress from GWAS. J. Autoimmun. 41: 25-33.
8. Morel, L. 2010. Genetics of SLE: evidence from mouse models. Nat. Rev. Rheumatol. 6: 348-357.
9. Kil, L. P., and R. W. Hendriks. 2013. Aberrant B cell selection and activation in systemic lupus erythematosus. Int. Rev. Immunol. 32: 445-470.
10. Rangel-Moreno, J., D. M. Carragher, M. de la Luz Garcia-Hernandez, J. Y. Hwang, K. Kusser, L. Hartson, J. K. Kolls, S. A. Khader, and T. D. Randall. 2011. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat. Immunol. 12: 639-646.
11. Vinuesa, C. G., I. Sanz, and M. C. Cook. 2009. Dysregulation of germinal centres in autoimmune disease. Nat. Rev. Immunol. 9: 845-857.
12. Li, X. Y., Z. B. Wu, J. Ding, Z. H. Zheng, X. Y. Li, L. N. Chen, and P. Zhu. 2012. Role of the frequency of blood CD4(+) CXCR5(+) CCR6(+) T cells in autoimmunity in patients with Sjögren's syndrome. Biochem. Biophys. Res. Commun. 422: 238-244.
13. Ueno, H., J. Banchereau, and C. G. Vinuesa. 2015. Pathophysiology of T follicular helper cells in humans and mice. Nat. Immunol. 16: 142-152.
14. Tangye, S. G., C. S. Ma, R. Brink, and E. K. Deenick. 2013. The good, the bad and the ugly-TFH cells in human health and disease. Nat. Rev. Immunol. 13: 412-426.
15. Karnowski, A., S. Chevrier, G. T. Belz, A. Mount, D. Emslie, K. D'Costa, D. M. Tarlinton, A. Kallies, and L. M. Corcoran. 2012. B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1. J. Exp. Med. 209: 2049-2064.
16. Xu, H., X. Li, D. Liu, J. Li, X. Zhang, X. Chen, S. Hou, L. Peng, C. Xu, W. Liu, et al. 2013. Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility. Nature 496: 523-527.
17. Deenick, E. K., A. Chan, C. S. Ma, D. Gatto, P. L. Schwartzberg, R. Brink, and S. G. Tangye. 2010. Follicular helper T cell differentiation requires continuous antigen presentation that is independent of unique B cell signaling. Immunity 33: 241-253.
18. Gitlin, A. D., Z. Shulman, and M. C. Nussenzweig. 2014. Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature 509: 637-640.
19. Yu, D., A. H. Tan, X. Hu, V. Athanasopoulos, N. Simpson, D. G. Silva, A. Hutloff, K. M. Giles, P. J. Leedman, K. P. Lam, et al. 2007. Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature 450: 299-303.
20. Bubier, J. A., T. J. Sproule, O. Foreman, R. Spolski, D. J. Shaffer, H. C. Morse, III, W. J. Leonard, and D. C. Roopenian. 2009. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc. Natl. Acad. Sci. USA 106: 1518-1523.
21. Kil, L. P., M. J. de Bruijn, M. van Nimwegen, O. B. Corneth, J. P. van Hamburg, G. M. Dingjan, F. Thaiss, G. F. Rimmelzwaan, D. Elewaut, D. Delsing, et al. 2012. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 119: 3744-3756.
22. Yu, L., A. J. Mohamed, L. Vargas, A. Berglöf, G. Finn, K. P. Lu, and C. I. Smith. 2006. Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase Pin1. J. Biol. Chem. 281: 18201-18207.
23. Belver, L., V. G. de Yébenes, and A. R. Ramiro. 2010. MicroRNAs prevent the generation of autoreactive antibodies. Immunity 33: 713-722.
24. Nisitani, S., A. B. Satterthwaite, K. Akashi, I. L. Weissman, O. N. Witte, and M. I. Wahl. 2000. Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells. [Published erratum appears in 2000 Proc. Natl. Acad. Sci. USA 97: 5679.] Proc. Natl. Acad. Sci. USA 97: 2737-2742.
25. Hutcheson, J., K. Vanarsa, A. Bashmakov, S. Grewal, D. Sajitharan, B. Y. Chang, J. J. Buggy, X. J. Zhou, Y. Du, A. B. Satterthwaite, and C. Mohan. 2012. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. Arthritis Res. Ther. 14: R243.
26. Chang, B. Y., M. M. Huang, M. Francesco, J. Chen, J. Sokolove, P. Magadala, W. H. Robinson, and J. J. Buggy. 2011. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res. Ther. 13: R115.
27. Honigberg, L. A., A. M. Smith, M. Sirisawad, E. Verner, D. Loury, B. Chang, S. Li, Z. Pan, D. H. Thamm, R. A. Miller, and J. J. Buggy. 2010. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. USA 107: 13075-13080.
28. Di Paolo, J. A., T. Huang, M. Balazs, J. Barbosa, K. H. Barck, B. J. Bravo, R. A. Carano, J. Darrow, D. R. Davies, L. E. DeForge, et al. 2011. Specific Btk inhibition suppresses B cell-and myeloid cell-mediated arthritis. Nat. Chem. Biol. 7: 41-50.
29. Mina-Osorio, P., J. LaStant, N. Keirstead, T. Whittard, J. Ayala, S. Stefanova, R. Garrido, N. Dimaano, H. Hilton, M. Giron, et al. 2013. Suppression of glomerulonephritis in lupus-prone NZB 3 NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase. Arthritis Rheum. 65: 2380-2391.
30. Rankin, A. L., N. Seth, S. Keegan, T. Andreyeva, T. A. Cook, J. Edmonds, N. Mathialagan, M. J. Benson, J. Syed, Y. Zhan, et al. 2013. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. J. Immunol. 191: 4540-4550.
31. Xu, D., Y. Kim, J. Postelnek, M. D. Vu, D. Q. Hu, C. Liao, M. Bradshaw, J. Hsu, J. Zhang, A. Pashine, et al. 2012. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J. Pharmacol. Exp. Ther. 341: 90-103.
32. Hendriks, R. W., R. G. Bredius, K. Pike-Overzet, and F. J. Staal. 2011. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. Expert Opin. Ther. Targets 15: 1003-1021.
33. Maas, A., G. M. Dingjan, F. Grosveld, and R. W. Hendriks. 1999. Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinase mutant under the control of the CD19 promoter region. J. Immunol. 162: 6526-6533.
34. Renshaw, B. R., W. C. Fanslow, III, R. J. Armitage, K. A. Campbell, D. Liggitt, B. Wright, B. L. Davison, and C. R. Maliszewski. 1994. Humoral immune responses in CD40 ligand-deficient mice. J. Exp. Med. 180: 1889-1900.
35. Corneth, O. B., A. M. Mus, P. S. Asmawidjaja, R. G. Klein Wolterink, M. van Nimwegen, M. D. Brem, Y. Hofman, R. W. Hendriks, and E. Lubberts. 2014. Absence of interleukin-17 receptor a signaling prevents autoimmune inflammation of the joint and leads to a Th2-like phenotype in collagen-induced arthritis. Arthritis Rheumatol. 66: 340-349.
36. Hutloff, A., K. Buchner, K. Reiter, H. J. Baelde, M. Odendahl, A. Jacobi, T. Dörner, and R. A. Kroczek. 2004. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum. 50: 3211-3220.
37. Dong, C., A. E. Juedes, U. A. Temann, S. Shresta, J. P. Allison, N. H. Ruddle, and R. A. Flavell. 2001. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409: 97-101.
38. McAdam, A. J., R. J. Greenwald, M. A. Levin, T. Chernova, N. Malenkovich, V. Ling, G. J. Freeman, and A. H. Sharpe. 2001. ICOS is critical for CD40-mediated antibody class switching. Nature 409: 102-105.
39. Tafuri, A., A. Shahinian, F. Bladt, S. K. Yoshinaga, M. Jordana, A. Wakeham, L. M. Boucher, D. Bouchard, V. S. Chan, G. Duncan, et al. 2001. ICOS is essential for effective T-helper-cell responses. Nature 409: 105-109.
40. Mak, T. W., A. Shahinian, S. K. Yoshinaga, A. Wakeham, L. M. Boucher, M. Pintilie, G. Duncan, B. U. Gajewska, M. Gronski, U. Eriksson, et al. 2003. Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cell-dependent B cell responses. Nat. Immunol. 4: 765-772.
41. Lee, S. K., D. G. Silva, J. L. Martin, A. Pratama, X. Hu, P. P. Chang, G. Walters, and C. G. Vinuesa. 2012. Interferon-g excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. Immunity 37: 880-892.
42. Vinuesa, C. G., M. A. Linterman, C. C. Goodnow, and K. L. Randall. 2010. T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol. Rev. 237: 72-89.
43. Fagarasan, S., and T. Honjo. 2000. T-Independent immune response: new aspects of B cell biology. Science 290: 89-92.
44. Martini, H., V. Enright, M. Perro, S. Workman, J. Birmelin, E. Giorda, I. Quinti, V. Lougaris, M. Baronio, K. Warnatz, and B. Grimbacher. 2011. Importance of B cell co-stimulation in CD4(+) T cell differentiation: X-linked agammaglobulinaemia, a human model. Clin. Exp. Immunol. 164: 381-387.
45. Linterman, M. A., W. Pierson, S. K. Lee, A. Kallies, S. Kawamoto, T. F. Rayner, M. Srivastava, D. P. Divekar, L. Beaton, J. J. Hogan, et al. 2011. Foxp3+ follicular regulatory T cells control the germinal center response. Nat. Med. 17: 975-982.
46. Chung, Y., S. Tanaka, F. Chu, R. I. Nurieva, G. J. Martinez, S. Rawal, Y. H. Wang, H. Lim, J. M. Reynolds, X. H. Zhou, et al. 2011. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat. Med. 17: 983-988.
47. Wing, J. B., W. Ise, T. Kurosaki, and S. Sakaguchi. 2014. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity 41: 1013-1025.
48. Sage, P. T., A. M. Paterson, S. B. Lovitch, and A. H. Sharpe. 2014. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity 41: 1026-1039.
49. Teichmann, L. L., D. Schenten, R. Medzhitov, M. Kashgarian, and M. J. Shlomchik. 2013. Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. Immunity 38: 528-540.
50. Ma, D. Y., and E. A. Clark. 2009. The role of CD40 and CD154/CD40L in dendritic cells. Semin. Immunol. 21: 265-272.
51. Kool, M., G. van Loo, W. Waelput, S. De Prijck, F. Muskens, M. Sze, J. van Praet, F. Branco-Madeira, S. Janssens, B. Reizis, et al. 2011. The ubiquitinediting protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity 35: 82-96.
52. Chappell, C. P., K. E. Draves, N. V. Giltiay, and E. A. Clark. 2012. Extrafollicular B cell activation by marginal zone dendritic cells drives T celldependent antibody responses. J. Exp. Med. 209: 1825-1840.
53. Coca, A., and I. Sanz. 2012. Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome. Curr. Opin. Rheumatol. 24: 451-456.
54. Navarra, S. V., R. M. Guzmán, A. E. Gallacher, S. Hall, R. A. Levy, R. E. Jimenez, E. K. Li, M. Thomas, H. Y. Kim, M. G. León, et al; BLISS-52 Study Group. 2011. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 377: 721-731.
55. Hendriks, R. W., S. Yuvaraj, and L. P. Kil. 2014. Targeting Bruton's tyrosine kinase in B cell malignancies. Nat. Rev. Cancer 14: 219-232.
56. Byrd, J. C., B. Harrington, S. O'Brien, J. A. Jones, A. Schuh, S. Devereux, J. Chaves,W. G.Wierda, F. T. Awan, J. R. Brown, et al. 2016. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med. 374: 323-332.